Cabaletta Bio, Inc.
Status: Publicly traded
Direct answer
Cabaletta Bio, Inc. is publicly traded on NASDAQ under the ticker CABA.
Cabaletta Bio, Inc. is a biotechnology firm in the clinical development stage, specializing in the invention and advancement of sophisticated engineered T cell therapies. Its core mission is to treat autoimmune diseases where B cells are implicated in producing harmful autoantibodies. The company's unique chimeric autoantibody receptor (CAAR) T cell platform is engineered to precisely target and eradicate these...
Can you invest in Cabaletta Bio, Inc.?
Yes. Cabaletta Bio, Inc. is publicly traded on NASDAQ under the ticker CABA.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Cabaletta Bio, Inc.
Detailed equity research is provided by MarketSnap.